4m
Hosted on MSNDenali Therapeutics’ ALS therapy fails to meet primary endpoint in Phase II/III trialThe primary analysis included 186 subjects who received the therapy and 139 subjects who were given a placebo.
The unusual decision to has sparked discussion about the intersection of traditional Church hierarchy and Pope Francis’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results